๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 170 Beijing 4 Chengdu 4 Shijiazhuang 3 Fuzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin170 Beijing4 Chengdu4 Shijiazhuang3 Fuzhou2
All 32 locations
Target enrolment
to

Trials with a site in Chengdu

4 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
NCT07733830Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Recruiting
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
NCT07506109BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
49
Beijing, Wuhan, Chengdu, Tianjin
2026-03-01
Not yet open
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
NCT07246317Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
188
Guangzhou, Shijiazhuang, Luoyang, Nanyang, Chengdu, Tianjin, Jiaxing
2025-12-15
Recruiting
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
NCT05595590Head and Neck Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Chengdu, Tianjin
2022-10-20
Rows per page Showing 1–4 of 4
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4 of those studies with a site in Chengdu that also match the filters currently applied.

How many clinical trials are recruiting in Chengdu?

3 of the 4 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chengdu), 4 studies
PhaseStudiesRecruitingShare
Phase 243100%

Most active sponsors

Lead sponsors with the most studies (Chengdu)
Lead sponsorStudiesRecruiting
Tianjin Medical University Cancer Institute and Hospital43
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.